Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)

Wolter, Pascal; Stefan, C; Decallonne, Brigitte; Dumez, Herlinde; Fieuws, Steffen; Wildiers, Hans; Clément, Paul M.; Debaere, Debbie; Oosterom, A. Van; Schöffski, Patrick

doi:10.1200/jco.2008.26.15_suppl.5126

Cited by 37 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hypothyroidism following RT is a predictor of better survival in head and neck cancer patients (228). Propylthiouracil-induced hypothyroidism was associated with improved survival in patients with high-grade glioma (229). IFN-and IL2-induced thyroid autoimmunity correlated with better prognosis in various studies (64,65,81,83), but not when guarantee-bias survival analyses were performed (39,49,60).…”

Section: Why Is It Important To Assess Thyroid Function In Cancer Patmentioning

confidence: 98%

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Torino

Barnabei²,

Paragliola

et al. 2013

Thyroid

103

View full text Add to dashboard Cite

Section: Why Is It Important To Assess Thyroid Function In Cancer Patmentioning

confidence: 98%

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Torino

Barnabei²,

Paragliola

et al. 2013

Thyroid

103

View full text Add to dashboard Cite

“…Possible mechanisms include the induction of a destructive thyroiditis (4,7,8), the inhibition of peroxidase activity (9), the blocking of iodine uptake (10), irreversible thyroid destruction (11), or capillary dysfunction (9,12), targeting vascular endothelial growth factor (VEGF) receptors via its antiangiogenic activity. Due to the high incidence of hypothyroidism in patients treated with sunitinib, a routine control algorithm has recently been proposed (13). However, hypothyroidism does not require the interruption of treatment per se since replacement with levothyroxine seems to be effective (5,6).…”

Section: Introductionmentioning

confidence: 99%

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Kim

Schwarz²,

Nogai³

et al. 2010

Thyroid

View full text Add to dashboard Cite

Background: Thyroid dysfunction is a well-known adverse effect of first-generation tyrosine kinase inhibitors (TKIs), like sunitinib. The aim of this study was to investigate the effect of second-generation TKIs on thyroid function. Methods: We retrospectively assessed the effect of the first-generation TKI imatinib and the second-generation TKI nilotinib and dasatinib on thyroid function tests in 73 Philadelphia chromosome-positive (Ph-positive) chronic myeloid leukemia patients. Results: Overall, 33 of 73 (45%) had one or more thyroid function test abnormalities during follow-up. Hypothyroidism or hyperthyroidism were found in 18 of 73 (25%) and 21 of 73 (29%) cases after a median of 6 and 22 weeks, respectively. In most patients (29 of 39, 74%) thyroid dysfunction was transient without clinical symptoms. Therapy of hypo-/hyperthyroidism was required in three patients. Thyroid dysfunction never resulted in the discontinuation of TKI therapy. Under treatment with imatinib, nilotinib, and dasatinib, thyroid abnormalities were detected in 25%, 55%, and 70%, respectively. Four of 55 patients (7%) treated with nilotinib had evidence for an autoimmune thyroiditis (antibody positive in 3 of 4 patients) with an episode of hyperthyroidism preceding hypothyroidism. Conclusions: Thyroid dysfunction is a common adverse event with second-generation TKI therapy in patients with Ph-positive chronic myeloid leukemia. Although the mechanism is still unclear, the high frequency of thyroid abnormalities, including autoimmune thyroiditis, warrants regular and long-term monitoring of thyroid function in these patients.

show abstract

“…The question of thyroid hormone substitution in TKIinduced hypothyroidism has been raised recently following the publication of a report which concluded that the median progression-free survival in sunitinibtreated patients for renal carcinoma cell was better in patients with thyroid abnormalities (40)(41)(42). Even though levothyroxine therapy remains debated in patients with asymptomatic or subclinical hypothyroidism, levothyroxine seems to be necessary in TKI-induced overt hypothyroidism in order to avoid the symptoms of hypothyroidism.…”

Section: Sorafenib (Bay 43-9006)mentioning

confidence: 99%

Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

Illouz

Laboureau-Soares²,

Dubois³

et al. 2009

European Journal of Endocrinology

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKI) belong to new molecular multi-targeted therapies that are approved for the treatment of haematological and solid tumours. They interact with a large variety of protein tyrosine kinases involved in oncogenesis. In 2005, the first case of hypothyroidism was described and since then, some data have been published and have confirmed that TKI can affect the thyroid function tests (TFT). This review analyses the present clinical and fundamental findings about the effects of TKI on the thyroid function. Various hypotheses have been proposed to explain the effect of TKI on the thyroid function but those are mainly based on clinical observations. Moreover, it appears that TKI could alter the thyroid hormone regulation by mechanisms that are specific to each molecule. The present propositions for the management of TKI-induced hypothyroidism suggest that we assess the TFT of the patients regularly before and during the treatment by TKI. Thus, a better approach of patients with TKI-induced hypothyroidism could improve their quality of life.

show abstract

Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)

Cited by 37 publications

References 0 publications

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

Contact Info

Product

Resources

About